# Schrodinger, Inc. Common Stock (SDGR)

> Schrodinger, Inc. Common Stock (SDGR) trades at $32.93 (+1.60%) as of 9:25:10 AM EST on Nov 11, 2026, +25.09% over the past month. Market cap is $2.43B, with 5.8 days to cover in short interest.

Canonical: https://massive.com/quote/sdgr
Data as of: 2026-11-11T14:25:10.005Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$32.93** +0.52 (+1.60%)
As of 9:25:10 AM EST on Nov 11, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Schrodinger, Inc. Common Stock (SDGR) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -2.94% |
| 1W | +19.24% |
| 1M | +25.09% |
| YTD | +81.26% |
| 1Y | +80.26% |
| 52-wk range | $10.95 – $33.78 |

From daily closes through Nov 10, 2026.

## Key statistics

Today's trading snapshot for SDGR: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | — |
| Open | — |
| Prev close | $32.41 |
| Volume | 16.32K |
| Market cap | $2.43B |
| Shares out | 65.91M |

## Valuation and profitability ratios

Valuation and profitability ratios for Schrodinger, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 9.04 |
| P/B | 8.06 |
| P/FCF | — |
| ROE | -19.6% |
| ROA | -9.7% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 10, 2026

## Insider trading

[Schrodinger, Inc. Common Stock (SDGR) insider trading](https://massive.com/quote/sdgr/insider-trading.md): open-market Form 4 buys and sells by Schrodinger, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Schrodinger, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · Business update
  “The abstract stated that the Company has an ongoing combination study of SGR-1505 in patients with relapsed/refractory B cell malignancies. The Company has in fact not initiated a combination study of SGR-1505 under its FDA-cleared protocol and, as previously disclosed, is exploring strategic opportunities to continue development of SGR-1505.”
- Jun 29, 2026 · Acquisition completion
  “In connection with the completion of Eli Lilly and Company's acquisition of Ajax Therapeutics, Inc. ("Ajax"), a company co-founded by Schrödinger, Inc. (the "Company"), the Company received a cash payment of approximately $57 million. The Company is also eligible to receive additional cash payments upon the achievement by Ajax of specified clinical and regulatory milestones.”
- Jun 23, 2026 · Equity compensation grant
  “The Company's stockholders approved an amendment (the '2026 Plan Amendment') to the Schrödinger, Inc. 2022 Equity Incentive Plan, as amended (the '2022 Equity Incentive Plan'). The 2026 Plan Amendment... increases the number of shares of common stock of the Company available for issuance under the 2022 Equity Incentive Plan by 3,000,000 shares.”
- Jun 8, 2026 · Executive compensation change
  “Pursuant to the Separation Agreement, Mr. Aklian is entitled to receive certain payments and benefits in connection with his separation that are substantially comparable to the previously-disclosed benefits he would have received pursuant to the terms of the employment agreement, dated as of May 9, 2025... including: (i) salary continuation payments of his monthly base salary, commencing on the first payroll period occurring on or after the day immediately following the Revocation Period, and continuing for nine months thereafter... (ii) payment on Mr. Aklian's behalf of the portion of his COBRA premiums equal to the premiums that the Company pays on behalf of other active, similarly-situated employees for group health and/or dental insurance coverage, if Mr. Aklian timely elects to receive such coverage, for 12 months following Mr. Aklian's separation from the Company.”
- May 20, 2026 · [Guidance issuance or update](https://massive.com/quote/sec-filings/8-k/guidance-updates.md)
  “The Company reaffirms the full-year and second quarter 2026 financial and operational guidance provided in connection with the Company's first quarter 2026 earnings release, as set forth in the Company's press release dated May 5, 2026.”

## SDGR short interest

How heavily SDGR is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 5.8 |
| Short interest | 9.75M |
| Avg volume | 1.67M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## SDGR news

The latest news and headlines about Schrodinger, Inc. Common Stock (SDGR).

- [Schrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates](https://www.zacks.com/stock/news/3023617/schrodinger-inc-sdgr-reports-q3-loss-beats-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3023617) · Zacks Investment Research · Nov 4, 2026 · positive sentiment
- [SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates](https://www.zacks.com/stock/news/3021446/sophia-genetics-sa-soph-reports-q3-loss-beats-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3021446) · Zacks Investment Research · Nov 3, 2026 · negative sentiment
- [Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?](https://www.zacks.com/stock/news/3000687/schrodinger-sdgr-surges-7-6-is-this-an-indication-of-further-gains?cid=CS-ZC-FT-fundamental_analysis|daily_price_change_5%-3000687) · Zacks Investment Research · Oct 6, 2026 · positive sentiment
- [Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 \| Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities](https://www.globenewswire.com/news-release/2026/10/05/3374241/28124/en/global-drug-discovery-ai-tools-market-strategic-forecast-2026-2032-generative-ai-cloud-platforms-and-integrated-r-d-workflows-create-new-growth-opportunities.html) · GlobeNewswire Inc. · Oct 5, 2026 · positive sentiment
- [Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine Demand](https://www.globenewswire.com/news-release/2026/09/23/3367233/28124/en/biosimulation-market-set-for-strong-growth-through-2035-fueled-by-ai-driven-drug-discovery-virtual-trials-and-precision-medicine-demand.html) · GlobeNewswire Inc. · Sep 23, 2026 · positive sentiment

## About Schrodinger, Inc. Common Stock

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 850 |
| Listed | Feb 6, 2020 |

[Company website](https://www.schrodinger.com)

## FAQ

### What is the Schrodinger, Inc. Common Stock (SDGR) stock price today?

Schrodinger, Inc. Common Stock (SDGR) is trading at $32.93 (+1.60% on the day) as of 9:25:10 AM EST on Nov 11, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Schrodinger, Inc. Common Stock?

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery.

### What is the short interest in SDGR?

As of Oct 30, 2026, SDGR has 9.75M shares short and 5.8 days to cover.

### What exchange is SDGR listed on?

Schrodinger, Inc. Common Stock (SDGR) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time SDGR quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=SDGR`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Schrodinger, Inc. Common Stock (SDGR) insider trading](https://massive.com/quote/sdgr/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms